<DOC>
	<DOCNO>NCT00667862</DOCNO>
	<brief_summary>This Phase II single dose study design characterize safety , tolerability efficacy i.v . panobinostat single-agent treatment patient hormone refractory prostate cancer .</brief_summary>
	<brief_title>Efficacy Safety Study Panobinostat Patients With Metastatic Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Inclusion criterion : Confirmed diagnosis adenocarcinoma prostate Patients metastatic hormone refractory prostate cancer Patients least one , two prior cytotoxic treatment prostate cancer Evidence disease progression least one follow 1. two lesion bone scan 2. progressive measurable disease 3. two documented increase PSA Willing use contraception throughout study 12 week study completion Exclusion criterion : History clinical sign CNS disease History cancer curatively treat evidence disease 5 year Prior radiotherapy within 3 week start study treatment Prior radiopharmaceutical ( strontium , samarium ) Impaired cardiac function Heart disease Liver renal disease impair function Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Prostate-Specific Antigen</keyword>
	<keyword>metastatic</keyword>
	<keyword>male</keyword>
	<keyword>HRPC</keyword>
	<keyword>DACi</keyword>
</DOC>